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Effects of Low Dose Transdermal Scopolamine on Heart Rate
Variability in Acute Myocardial Infarction
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Objectives . We hypothesized that by enhancing parasympa.
thetic activity, low dose trans dermal scopolamine would increase
heart rate variability after myocardial infarction .
Background.
Low heart rate variability is associated with
increased mortality after acute myocardial infarction .
Methods. Conventional time domain heart rate variability was
measured from U-h loiter recordings of 61 consecutive male
patients (mean age 58 :k 10 years, left ventricular ejection fraction
44,7 ± 15,5%) 6 days (median) after acute myocardial infarction .
Patients were then randomly assigned to wear one patch of
tramidermal scopolamine or a matching placebo patch for 24 h,
during which their 24-h heart rate variability was renieasured .
A decrease in heart rate variability measured after acute
myocardial infarction predicts subsequent total mortality
and arrhythmic events (1-10). It has been postulated that
such decrease in heart rate regulation reflects altered sym-
pathovagal neurocardiac reflex regulation with either in-
creased sympathetic or decreased parasympathetic activity,
or both (11-17). Although the reduction in hyperadrenergic
activity by beta-adrenergic receptor blockade has proved
successful in reducing postinfarct morbidity and mortality,
the protective effect of vagal stimulation has only recently
received increased attention (18,19) . Direct vagal nerve
stimulation in the dog model significantly reduces ischemic
injury after coronary artery occlusion (20) and protects
nst ventricular fibrillation (21). Similarly, pharmacologic
stimulation of the vagus with low dose atropine (22), neostig-
rain: (20 carbachohne, cyclic guanosine monophosphate
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Results . Compared with placebo, transdermal scopolamine
caused a significant increase in time domain treasures of 24-h
heart rate variability by 26% to 35% above baseline. Transdermal
scopolamine was well tolerated .
Conclusions . Low dose transdermal scopolamine safely in-
creases cardiac parasympathetic activity and short-term heart
rate variability after acute myocardial infarction . Whether the
effect of transdermal scopolamine on heart rate variability is a
reasonable surrogate for improvement of long-term morbidity and
mortality requires an appropriately designed investigation .
(I Ant Coil Cardiol 1993 ;22:1320-6)
(24), methacholine and oxotremorine (25) has been shown to
reduce ventricular vulnerability in ischemic dog hearts . No
corresponding studies have been performed in humans to
date. We therefore investigated the feasibility and safety of
pharmacologic parasympathetic stimulation in acute myo-
cardial infarction and measured the effects of low dose
transdermal scopolamine (26) on heart rate variability, a
marker of cardiac parasympathetic activity, in human sub-
jects during the early days after acute myocardial infarction .
Previous studies in healthy human subjects have shown that
low dose transdermal delivery of scopolamine increased
arterial baroreflex sensitivity and heart rate variability, pre-
sumably by a parasympathomimetic mode of action (27,28) .
Whods
Subjects. The study was approved by the Institutional
Review Board of Baylor College of Medicine and the Hous-
ton Veterans Affairs Medical Center. Sixty-one men, con
secutive patients with acute myocardial infarction in the
coronary care unit, consented to participate in the study .
Patients were enrolled between July 1990 and September
1991 . All subjects had the diagnosis of acute myocardial
infarction established independently by their primary physi-
cian, based on characteristic symptoms, electrocardio-
graphic (ECG) changes and supranormal elevation in total
and serum creatine kinase, MB fraction (CK-MB) levels . By
the time of enrollment, the patients were free of chest pair
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and did not require vasopressor or inotropic medications . All
patients were in sinus rhythm . While participating in the
study, all subjects were under the caie of their primary
physician and were receiving standard medical care . Their
level of physical activity was as tolerated . Patients with a
history of glaucoma and urinary retention were excluded .
Study pomaK On enrollment, subjects were randomly
assigned to the placebo and scopolamine study arms and
underwent a baseline 24-h Holler ambulatory BCC) record-
ing. The study medication (scopolamine or matching pla-
cebo) was then administered in a double-blind fashion in the
form of a single transdermal therapeutic system (TTS) patch,
applied behind the ear, as recommended by the manufac-
turer (Ciba Consumer Pharmaceuticals) . After wearing the
patch for 4 h, an "intervention" 24-h Holler ECG was
recorded, during which the patch remained in place .
Throughout the study, subjects were observed and ques-
tioned for adverse effects and underwent continuous cardiac
rhythm monitoring . Clinical information was obtained
through patient interview and review of the medical record .
Left ventricular ejection fraction was calculated by echocar-
diography (51%), cardiac catheterization (46%) or by gated
wall motion study (3%) during the same hospital period .
low recording and processing. All Holier tapes were re-
corded on Marquette Electronics hic . analog cassette dual-
channel recorders that include a timing track . Tapes were
analyzed by a single experienced technician on a Marquette
Electronics 8000 Holter research system (analog/digital
128 Hz). Beat by beat annotation of normal (sinus) beats,
nonsinus beats and artifact was performed during visual scan-
ning of the data. Annotated event files were generated using the
QRSDK program provided by Marquette Electronics and were
transmitted to a VAX computer (Digital Equipment Corp.) for
further analysis . Based on the original beat annotation code,
secondary files containing only normal to normal interbeat
intervals were generated . Postectopic normal to normal inter-
vals were included in the analysis .
Heart rate variability measures. The following conventional
time domain indexes of heart rate variability were calculated
for the entire Holler recording : 1) global standard deviation
(SD) of all normal to normal intervals (1,2,10,29,30) ; 2) mean
value of the SDs of consecutive 5-min segments (10,29,30) ; 3)
SD of the mean values of consecutive 5-min segments (29,30) ;
and 4) root-mean-squared successive normal to normal differ-
ences (13). The latter was computed only when normal beats
occurred in groups of three or more .
As a consequence of signal loss, excessive ectopic activ-
ity or noise, it was not possible to analyze all 5-min segments
of every recording . An arbitrary lower bound of 10 was
placed on the number of normal to normal intervals required
for acceptability of a 5-min segment . However, the over-
whelming majority of segments contained >100 normal to
normal intervals . Using the mean heart rate over the entire
recording, an estimated number of normal to normal inter-
vals per 5-min segment were calculated . For patients in the
scopolamine group, the average percent of expected inter-
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vats in analyzed segments was 87
.7%, whereas for the
placebo group, the average number of intervals analyzed per
5-min segment was 91
.7% of the expected number . Four
scopolamine tapes (three patients) had ratios <50%, but no
placebo group patient had a ratio below this level .
Statistical analysis . Between-group data comparisons
were performed using the Mann-Whitney test and, where
appropriate, the two-sided Fisher exact test . Spearman rank
correlation coefficients (r,) and the corresponding test of
significance were used to nonparametrically assess relation
between variables . Linear regression was used to assess
treatment-covariate interactions (BMDP Statistical Soft-
ware, Inc .). Nonparametric statistical methods were used
when possible because the variables generally did not exhibit
a normal distribution . Statistical significance was accepted if
p < 0.05. No adjustment for multiple comparisons was
made. Because of the small group size, we elected not to
perform an analysis of covariance with regard to baseline
clinical variables and equally did not adjust our results for
concomitant therapy .
Results
Clinical characteristics . Sixty-one consecutive male pa-
tients (mean age 58 ± 10 years, left ventricular ejection
fraction 44.7 ± 15 .5%) were enrolled 6 days (median) after
acute myocardial infarction . Clinical data of the scopolamine
and placebo patient groups are summarized in Table 1 . Both
groups were comparable with respect to age, previous
cardiac history, myocardial infarction location, presence of
Q waves on the ECG and serum creatine kinase (CK) level
(all p > 0 .1) . Left ventricular ejection fraction was margin-
ally lower in the scopolamine group (p = 0.06). Seventy-five
percent of the patients underwent coronary arteriograpby .
Single-vessel coronary artery disease was present in 35%
and 29% of the scopolamine and placebo group patients,
respectively . Two-vessel disease was found in 30% and 25%
and three-vessel disease in 35% and 46% of the scopolamine
and placebo group patients, respectively (all p > 0 .1). Four
patients in the scopolamine group used digitalis preparations
in contrast to none of the patients receiving placebo (p =
0.52). Nonstudy medications were not changed between
baseline and intervention .
Heart rate variability after acute myocardial infarction .
Of 61 randomized study subjects, 58 completed both Holter
recordings. One patient (randomized to the scopolamine
group) completed only a baseline recording because of early
discharge from the hospital . In two scopolamine group
patients, the baseline Holter tape could not be analyzed
because of technical difficulty with the data acquisition .
There was no difference between the placebo and scopol-
amine groups with regard to the time interval between
myocardial infarction and the baseline and intervention
Holier recordings, respectively (Table 2) .
Baseline heart rate variability did not differ between the
scopolamine and placebo groups (all p > 0
.05) (Table 2) .
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Table 1 .
Comparison of Baseline Clinical Characteristics for Scopolamine and Placebo
Group Patients
seline heart rate variability correlated with left ventricular
ejection fraction (r5 = 0.33 - 0.49, all p < 0 .02) but was not
related to peak serum CIA level, CK-ME fraction, history of
thrombolysis, presence of a Q wave on the initial ECG,
infarct location or history of previous myocardial infarction
(all p > 0, 1). Although 33 patients who received beta-
Table 2 . Sequential Measures of Heart Rate Variability
*Comparison
by Mann-Whitney test, Fisher exact test . Unless otherwise indicated, values presented are median
value (25th, 75th quartile) or number of patients
. ACE = angiotensin-converting enzyme : CK = creatine kinase ;
CK-MB = creatine kinase, ME fraction: LVEF
= left ventricular gicction fraction ; Post-MI = after myocardial
infarction,
blockers had a slower heart rate (mean normal to normal
interval 879 ± 136 ms [mean ± SD]) than that of 26 patients
who did not receive beta-blocke. s (mean normal to normal
interval 809 ± 213 ms, p = 0 .04), both groups had compa-
rable heart rate variability (all p > 0.3) .
A moderately strong correlation was observed among the
*p > 0 .05, placebo - scopolamine (baseline - intervention)
. tp < 0.05, scopolamine (baseline - intervention) .
0 < 0.01, scopolamine (baseline - intervention). §p < 0 .01, placebo - scopolamine (intervention). Data are
presented as median value
(25th, 75th quartile). Comparison by Mann-Whitney test . MN = mean normal to normal
interval; MNSD = mean of 5-min SDs ; Post-MI = after myocardial infarction ; rMSSD = root-mean-squared
successive difference of normal to normal intervals
; SD = global standard deviation ; SDMN = SD of 5-min mean
normal to normal interval .
JACC Vol
. 22, No
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Scopolamine
(n = 30)
Placebo
(n = 31)
p Value
Age (yr)
62 (56,66)
59 (47,63)
0 .13*
Anterior infarct
14 16
0.61
Q wave
14
14 0.7
Thrombolysis
9
8 0 .72
Peak CK total
1,099
(621,1942) 718 (524,2344)
0 .47*
Peak CK-MB
(o) 10 (8,11)
8(7,11) 0 .17*
LVEF (%)
45 (31,52)
55 (33,60) 0 .06*
Post-MI heart failure
6
3
0 .26
Post-MI angina
16
10
0 .1
History
Previous Ml
I I
12 0 .87
Angina pectoris 22
21 0 .63
Coronary bypass surgery
4
8
0 .22
Heart failure I
1
0,93
Hypertension
19
14 0 .15
Diabetes mellitus 6
9 0 .41
Medication
Beta adrenergic blocking agent
17 16
0 .80
Calcium channel blocking
agent 15 13
0 .61
Nitrates
26
26 1 .00
ACE inhibitor
8 7 0 .77
Digitalis
4 0
0.052
Diuretic agents
6
2 0.15
Aspirin
27
28 1 .00
Heparin
11 11 1 .00
Baseline Intervention
Scopolamine
(n = 28)
Placebo
(n = 31)
Scopolamine
(n = 29)
Placebo
(n = 31)
Post-MI day 7(4,9)
6 (4,8)* 8(6,10) 8 (6,11)*
MN (ms) 827 (709,936) 837 (735,948)* 857 (695,999)t 844 (760,936)*
SD (ms) 77 (58 .105) 91(71,106)* 98 (65,1294 98 (81,113)*
MNSD (ms) 37 (26,56) 38 (28,54)* 52 (30,724 38 (32,49)*
SDMN (ms)
65 (49,82) 77 (61,91)* 84 (59,104)# 85 (69,102)*
rMSSD (ms)
23 (16,30) 22 (16,28)* 31 (21,41)r 23 (18,27)§
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`Fable 3. Comparison of Heart Rate Variability Changes
(Baseline - Intervention) Between Scopolamine and Placebo
*Median difference in heart rate variability between baseline and inter-
vention recordings (% change)
. CI = confidence interval ; other abbreviations
as in Table 2 .
various heart rate variability variables (r, = 0 .48 - 0.95, all
p < 0.0001) and between mean heart rate and heart rate
variability (I, , = 0.50 - 0.73, all p < 0 .0001) .
Effect of transdermall scopolamine on heart rate variability
after acute myocardial infarction . Table 2 compares heart
rate variability for the scopolamine and placebo groups at
baseline (6 .3 ± 2 .9 days after myocardial infarction) and
after intervention (9 .5 ± 8.2 days) . In all but five subjects,
heart rate variability increased with scopolamine . Global SD
increased by a median value of 34%, the mean value of the
SDs of consecutive 5-min segments by 35%, the SD of
consecutive 5-min mean values by 28% and the root-mean-
squared successive normal to normal interval difference by
26%. The respective changes in the placebo group were 8%,
3%, 6% and -3% (all p < 0.01) (Table 3) . The relative
difference between scopolamine and placebo was highly
significant for all four variables of heart rate variability .
Figure 1 shows the individual changes in global SD for all
study subjects before and after receiving placebo or scopol-
amine, respectively. The effects of scopolamine on heart rate
were smaller. The mean normal to normal interval increased
by 5.9%, whereas the corresponding change in the placebo
group was -1 .4% (p = 0 .04). There was a strong correlation
among the indexes of heart rate variability and heart rate,
with the following exceptions : the mean normal to normal
interval and SD of consecutive 5-min segments and the
root-mean-squared successive difference and SD of consec-
utive 5-min mean values, respectively (Table 4) . In light of
this apparent relation between changes in heart rate variabil-
ity and changes in heart rate, heart rate variability variables
were normalized for heart rate by dividing each individual
value by the corresponding mean normal to normal interval .
After this normalization, the effect of scopolamine (com-
pared with placebo) remained significant for the mean value
of the SDs of consecutive 5-min segments (p < 0 .0001), for
the SD of consecutive 5-min mean values (p = 0 .04) and for
the root-mean-squared successive normal to normal interval
difference (p = 0 .002). The effect of scopolamine on the
global SD was no longer apparent (p = 0 .96) .
Treatment-covariate interactions . The relation of clinical
variables at baseline to the treatment effect (scopolamine
.20
0
Patch
Figure 1 . Individual patient values of 24-h standard deviation (SD)
(s) at baseline and with patch for the scopolamine and placebo study
groups .
compared with placebo) on heart rate variability was exam-
ined. Because of the study size, the power in detecting
interaction effects was low . There was no uniform relation
between left ventricular ejection fraction, when dichoto-
mized at 40%, and treatment effect on heart rate variability
(global SD, p = 0 .05 ; mean value of the SDs of consecutive
5-min segments, p = 0 .23; SD of consecutive 5-min mean
Table 4
. Correlation of Heart Rate Variability Changes
(Baseline - Scopolamine)
Placebo
SD (ms) MNSD (ms) SDMN (ms) rMSSD (ms)
MN (ms) 0 .3 ., 0 .70
0 .17 0.73
(p=0.0105) (p<0.00(1) (p=0.21) (p<0.001)
SD (ms) 0 .60 0 .90
0.39
(1) < 0 .0001) (p < 0 .0001) (p = 6.0620)
MNSD (ms)
0 .36 0.81
(p = 0,0002) (p < 0-Wol)
SDMN (ms) 0.25
(p -10%64)
Values presented are Spearman rank correlation coefficients with corre-
sponding p values . Abbreviations as in Table 2 .
Scopolamine* Placebo,
Median
Difference
t95% Cl) p Value
MN (ms) 38 (+6%) 2 (+0.2%) 40 (1-85) 0.04
SD (ms) 26 (+34%) 7 (+8%) 20(9-.10) 0.0015
MNSD (ms) 13 (4-35%) 1(+3%) 14 (7-20) 0.001
SDMN (ms) 18 (+28%) 5(+617c) 15 (3-25) 0.009
rMSSD (ins) 6 (+26%)
-0.6(--3%) 7(2-13) 0.0017
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*Comparison by Fisher exact test (two-sided), pts - patients .
values, p = 0.06; root-mean-squared successive normal to
normal interval difference, p - 0.57) or when ejection
fraction was examined as a continuous variable (global SD,
p = 0.08; mean value of the SDs of consecutive 5-min
segments, p - 0.30; SD of consecutive 5-min mean values,
p = 0,04; root-mean-squared successive normal to normal
interval difference, p = 1 .00). Baseline global SD, dichoto-
mized at 50 ms, did not predict heart rate variability re-
sponse to treatment (all p > 0.2) . Myocardial infarction
location, the presence of a Q wave on the ECG, peak serum
CK level, history of thrombolysis and history of a previous
myocardial infarction were not related to treatment effect on
heart rate variability (all p > 0 .05). Subjects receiving
beta-blockers showed a heart rate variability response to
scopolamine (compared with placebo) similar to that of
subjects not receiving beta-blockers (all p > 0.2). The heart
rate variability measures (at baseline and after patch) of the
four subjects randomly assigned to receive scopolamine who
were also receiving digoxin, were not different from those of
the subjects randomly assigned to receive scopolamine who
were not taking digoxin (p > 0 .26).
Ad"rft eflects of kansdamal scopolamine. The overall
incidence of adverse effects was low . No patches were
removed before termination of the study . Table 5 lists the
subjective adverse effects during the study. Five patients
receiving scopolamine experienced dry mouth compared
with no patients receiving placebo (p = 0,024) . During the
study all patients were hemodynamically stable, and no
affhYthmias were observed . There was no exacerbation of
Ona, and no reinfarction occurred . There were no deaths .
ENSUCMUMSSdian
This randomized, placebo-controlled clinical trial de-
scribes the efficacy and safety of low dose transdermal
scopolamine in patients with acute myocardial infarction in
whom it caused a significant increase in heart rate variabil-
ity. The uniform increase in all four heart rate variability
variables of between 26% (root-mean-squared successive
normal to normal interval difference) and 35% (mean value
of the SD of consecutive 5-min segments) is consistent with
a previous report of transdermal scopolamine in young,
healthy volunteers, in whom an effect on short-term heart
rate variability of similar magnitude was observed (28) .
Recent reports (13-15,31,32) have established a strong
correlation between vagal neural activity and both time and
frequency domain indexes of heart rate variability . Our
findings of increased time domain variables of heart rate
variability by low dose scopolamine in myocardial infarction
are therefore consistent with a parasympathomimetic mode
of action. Similar to atropine, scopolamine exhibits oppos-
ing, dose-dependent effects. When used in high doses,
scopolamine blocks peripheral parasympathetic activity,
whereas at low doses, scopolamine exerts a paradoxic
parasympathomimetic effect that is purportedly mediated by
the central nervous system (46428,33-38) . Accordingly, by
providing continuous percutaneous low dose drug delivery,
the transdcrmal scopolamine therapeutic system (Transderm
Scop) has been shown to enhance both arterial baroreflex
sensitivity (27) and time and frequency domain indexes of
short-term heart rate variability (28) in healthy adults .
Previous studies (1,39) have demonstrated a close inter-
dependence of heart rate and heart rate variability . Although
the beneficial effect of beta-blockers appears to be related to
both a slowing of the heart rate and an increase in heart rate
variability (40-42), the cardioprotective effect of parasym-
pathetic stimulation may be less dependent on heart rate
reduction (1,12,24,25). Therefore, the rather modest brady-
cardia induced by scopolamine in this study does not neces-
sarily preclude a potential beneficial clinical effect. Patients
receiving beta-blockers experienced an increase in heart rate
variability similar to that of subjects not receiving beta-
blockers. Scopolamine increased heart rate variability in
subjects with left ventricular ejection fraction ranging from
12% to 66% and with baseline heart rate variability (global
SD) ranging from 22 to 132 ms.
It is unlikely that the study outcome was affected by
medication use because although the majority of cardiotro-
pic medications used by our patients affect heart rate vari-
ability (41-46), the treatment and control groups were com-
parable with respect to their use . Although four subjects
randomized to receive scopolamine were also receiving
digoxin, an agent with known parasympathetic activity, their
heart rate variability response to scopolamine was similar to
that of the other subjects receiving scopolamine . Both
groups were sirr ilar with respect to clinical variables known
to affect heart rate variability, notably age (14), extent of
coronary artery disease (47,48), prevalence of heart failure
(49,50) and of diabetes mellitus (51) .
Our findings are consistent with a previous report of a
beneficial antiarrhythmic and hemodynamic effect of paren-
temWl scopolamine after acute myocardial infarction (52) and
with previous smaller studies on the effects of transdermal
scopolamine after acute myocardial infarction (53-55) .
The present study focused exclusively on conventional
(time domain) statistics because they have been widely
applied and are being implemented in some commercial
Scopolamine
(no . of pts)
Placebo
(no . of pts) p Value*
Dry mouth 5 0
0 .024
Drowsiness 0
1 .000
Light-headedness 2 0 .61
Feeling "high" 3
2 0 .67
Headache 0 1 .00
Blurred vision I 0 .49
Confusion 0 1 .00
Dmuns I 0 0 .49
Urinary problems I 0 0 .49
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ambulatory ECG analysis systems . The application of spec-
tral analysis to loiter data remains problematic because of
unresolved questions relative to optimal data set size, non-
stationarity, the type of algorithm and the presence of
ectopic activity (15,56,57), Finally, a strong correlation has
been demonstrated between the 24-h root-mean-squared
successive normal to normal interval difference and the high
frequency component of the interbeat interval power spec-
trum, which is almost exclusively parasympathetically me-
diated (13) .
Study limitations. Our trial was not designed to assess the
morbidity and mortality effects of transdermal scopolamine .
Also, although we demonstrated a significant short-term
effect of scopolamine on cardiac parasympathetic activity,
this study was not designed to evaluate the long-term effi-
cacy and safety of transdermal scopolamine . In addition,
given the relatively low risk profile of our patient group, we
cannot describe its effects on patients who have a larger
infarct size and a lower left ventricular ejection fraction .
Conclusions . Decreased heart rate variability, reflecting
autonomic neurocardiac regulatory dysfunction, is associ-
ated with increased mortality after acute myocardial infarc-
tion. We demonstrated that low dose transdermal scopol-
amine increases heart rate variability with no observed
serious short-term toxicity after acute myocardial infarction .
Whether the effect of transdermal scopolamine on heart rate
variability is a reasonable surrogate for lessening of long-
term morbidity and mortality requires an appropriately de-
signed investigation .
We thank Claudia Alley for excellent secretarial support .
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